The claimed invention is:

1. A compound of formula (I):



I

including a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein:

R^1 is $(C_1\text{-}C_{10})$alkyl, $(C_3\text{-}C_{10})$cycloalkyl$(CH_2)_t$-, $(C_6\text{-}C_{10})$aryl$(CH_2)_t$-, or (5-10 membered heterocycle)$(CH_2)_t$-, wherein said R^1 is optionally substituted with at least one moiety selected from the group consisting of $(C_1\text{-}C_6)$ alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkoxy, oxo, and amino;

t is an integer from 0 to 5;

R^3 is (5-10 membered heteroaryl)$(CH_2)_s$ -, (5-10 membered heterocycle)$(CH_2)_s$ -, wherein said R^3 is optionally substituted with at least one moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkoxy, oxo, and amino; and

s is an integer from 0 to 5.

2. A compound of claim 1, wherein:

R^3 is a (2-pyridinyl)$(CH_2)_s$ -, (3-pyridinyl)$(CH_2)_s$ - or (4-pyridinyl)$(CH_2)_s$ -;

t is an integer from 0-4; and

s is an integer from 1-5.

3. A compound of claim 1, wherein R^1 is $(C_1\text{-}C_{10})$alkyl.

4. A compound of claim 1, wherein R^1 is $(C_3\text{-}C_{10})$cycloalkyl$(CH_2)_t$-.

5. A compound of claim 1, wherein R^1 is $(C_6\text{-}C_{10})$aryl$(CH_2)_t$-.

6. A compound of claim 5 wherein:

R^3 is a (2-pyridinyl)$(CH_2)_s$ -, (3-pyridinyl)$(CH_2)_s$ - or (4-pyridinyl)$(CH_2)_s$ -;
t is an integer from 0-4; and
s is an integer from 1-5.

7. A compound of claim 6, wherein:
t is an integer from 0-3; and
s is an integer from 1-3.

8. A compound of claim 1, wherein R^1 is (5-10 membered heterocycle)$(CH_2)_t$ -.

9. A compound of claim 8 wherein:
R^3 is a (2-pyridinyl)$(CH_2)_s$ -, (3-pyridinyl)$(CH_2)_s$ - or (4-pyridinyl)$(CH_2)_s$ -;
t is an integer from 0-4; and
s is an integer from 1-5.

10. A compound of claim 9, wherein:
t is an integer from 0-3; and
s is an integer from 1-3.

11. A compound of formula (II):



II

including a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein:

R^1 is C_1-C_{10} alkyl, (C_3-C_{10} cycloalkyl)$(CH_2)_t$ -, (C_6-C_{10} aryl)$(CH_2)_t$ -, or (5-10 membered heterocycle)$(CH_2)_t$ -, wherein said R^1 is optionally substituted with at least one moiety selected from the group consisting of (C_1-C_6)alkyl, halo, hydroxy, (C_1-C_6)alkoxy, halo(C_1-C_6)alkoxy, oxo, and amino;

t is an integer from 0 to 4;

R^4 is H or $(C_1\text{-}C_{10})$alkyl;

each R^5 is independently H, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_{10})$alkenyl, $(C_2\text{-}C_{10})$alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^6$, $-C(O)R^6$, $-C(O)OR^6$, $-NR^7C(O)OR^6$, $-OC(O)R^6$, $-NR^7SO_2R^6$, $-SO_2NR^6R^7$, $-NR^7C(O)R^6$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-S(O)_jR^8$, $-SO_3H$, $-NR^6(CR^7R^8)_pOR^7$, $-(CH_2)_p(C_6\text{-}C_{10}$ aryl), $-SO_2(CH_2)_p(C_6\text{-}C_{10})$aryl, $-S(CH_2)_p(C_6\text{-}C_{10})$aryl, $-O(CH_2)_p(C_6\text{-}C_{10})$aryl, $-(CH_2)_p$(5-10 membered heterocyclic), and $-(CR^7R^8)_mOR^7$;

m is an integer from 1 to 5;

p is an integer from 0 to 5;

j is an integer from 0 to 2;

each R^6 is independently selected from H, $(C_1\text{-}C_{10})$alkyl, $(C_6\text{-}C_{10})$aryl$(CH_2)_k$-, and (5-10 membered heterocyclic)$(CH_2)_k$-;

k is an integer from 0 to 5;

each R^7 and R^8 is independently H or $(C_1\text{-}C_6)$alkyl; and

n is an integer from 1 to 4.

12. A compound of claim 11 selected from the group consisting of:

5-[3-(2-Cyclohex-1-enyl-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2,5-Dimethyl-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(3,5-Dimethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Ethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(2-Ethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3,4-Dimethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-(3-Phenethyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Ethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Bromo-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Bromo-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(2-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(2-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(4-Ethoxy-3-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(2,5-Dimethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(3-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Difluoromethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2,6-Dimethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2,5-Dichloro-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(3-Morpholin-4-yl-propyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Morpholin-4-yl-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Diethylamino-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(3-Dimethylamino-propyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[2-(1-Methyl-pyrrolidin-2-yl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[3-(2-Methyl-piperidin-1-yl)-propyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

(R),(R)-5-[3-(2-Hydroxy-cycloheptylmethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

(R),(R)-5-[3-(2-Hydroxy-cyclooctylmethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Hydroxy-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2-Hydroxy-butyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-{3-[3-(2-Oxo-pyrrolidin-1-yl)-propyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(3-Imidazol-1-yl-propyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-(3-Benzyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-[3-(2,5-Difluoro-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

3-(1-Pyridin-3-yl-ethoxy)-5-(3-pyridin-2-ylmethyl-ureido)-isothiazole-4-carboxylic acid amide;

5-[3-(2,6-Dimethoxy-benzyl)-ureido]-3-(1-pyridin-3-yl-ethoxy)-isothiazole-4-carboxylic acid amide;

5-(3-Cyclopropylmethyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-(3-Methyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

5-(3-Methyl-ureido)-3-(1-pyridin-3-yl-ethoxy)-isothiazole-4-carboxylic acid amide; and

5-[3-(3,5-Dichloro-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12 and a pharmaceutically acceptable carrier.

14. A method of treating a TGF-related disease state in a mammal comprising the step of administering to the mammal suffering from the TGF-related disease state a therapeutically effective amount of a compound of any one of claims 1-12.

15. A method of claim 8, wherein said TGF-related disease state is selected from the group consisting of hyperproliferative disorders and fibrotic diseases.